Skip to main content
Premium Trial:

Request an Annual Quote

Tempus xR Sequencing Assay

Tempus launched a new standalone RNA next-generation sequencing assay this week, dubbed Tempus xR, which covers clinically relevant fusions in more than 100 targeted genes, as well as altered splicing for MET Exon 14 and EGFRvIII. The test falls under the firm's existing standard of whole-genome and exome sequencing, but Tempus described xR as a new option for physicians that are specifically interested in RNA fusions or altered splicing, as well as providers, researchers, and biopharma companies seeking RNA sequencing analysis of existing samples. According to the company, the launch will divide its current operations, with its xT assay now providing DNA sequencing and xR offering RNA sequencing for clinical and research use.